Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 2/24/14  and contains information from public web pages and contributions from the ZoomInfo community.

Mr. Doug Plessinger

Wrong Doug Plessinger?

Vice President , Clinical and Med...

Argos Therapeutics , Inc.
4233 Technology Dr
Durham, North Carolina 27704
United States

Company Description: Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer...   more
Background

Employment History

Board Memberships and Affiliations

  • Founder
    Axcelo MSL Solutions LLC

Education

  • B.S. degree , Pharmacy
  • Northeastern University
12 Total References
Web References
...
www.sec.gov, 6 Feb 2014 [cached]
0001542968 Plessinger Douglas C. C/O ARGOS THERAPEUTICS, INC. 4233 TECHNOLOGY DRIVE DURHAM NC 27704 0 1 0 0 See Remarks
Argos Therapeutics Management Team
www.argostherapeutics.com, 30 Sept 2013 [cached]
Doug Plessinger, RPh Vice President, Clinical and Medical Affairs
...
Doug Plessinger, RPh Vice President, Clinical and Medical Affairs Doug Plessinger joined Argos Therapeutics in 2011 after serving as a clinical consultant for the company for the previous 4 years. Prior to joining Argos, Mr. Plessinger was an original founder and served as the Executive Vice President and Managing Director for Axcelo MSL Solutions, a Medical Affairs and MSL consulting company. Prior to this, he served as Senior Vice President of Client Services at The Navicor Group and in other roles with Navicor and affiliated inVentiv Health companies from 2003 to 2007. Mr. Plessinger also served as a lead Medical Science Liaison (MSL) for Millennium Pharmaceuticals and held various roles of increasing responsibility for Bristol-Myers Squibb in Oncology Medical Affairs and Oncology Global Marketing from 1997 - 2003. Overall, he has more than 20 years of clinical pharmacy, pharmaceutical, and client-services related experience, including the development and launch of multiple oncology products across various solid and hematologic malignancies. Mr. Plessinger holds a B.S. degree in Pharmacy and graduated summa cum laude from Northeastern University.
Axcelo MSL Solutions - Doug Plessinger, RPh
www.axcelo.com, 21 July 2011 [cached]
Doug Plessinger, RPh Axcelo MSL Solutions - Doug Plessinger, RPh Axcelo MSL Solutions
...
Photo of Doug Plessinger, RPh
...
Doug Plessinger, RPh EVP, Managing Director Axcelo MSL Solutions, LLC
With more than 18 years of clinical pharmacy, pharmaceutical, and client-services experience, Doug leads Axcelo's business-development efforts and oversees the company's day-to-day operations. He also serves as a field-based medical consultant and an MSL for current clients. In this role, he continues to work directly with leading cancer institutions, investigators, and thought leaders across tumor types in order to advance and accelerate the development of novel oncology products and diagnostics.
During his career, Doug has held roles in Medical Affairs in addition to Global Marketing and Product Planning at Bristol-Myers Squibb. He has also been an accomplished MSL for other corporations, including Millennium Pharmaceuticals.
Prior to establishing Axcelo MSL Solutions, Doug was Senior Vice President of Client Services at The Navicor Group, an inVentiv Health company. He has led several oncology products and launches, including Vidaza (MDS), Alimta (Mesothelioma), Gemzar (MBC), Rituxan (NHL), Xeloda (MBC and CRC), Bondronat (MBD), and MK-0457 (resistant CML). While at Millennium, Doug supported the launch of an MSL program and the initial launch of Velcade for multiple myeloma.
Email Doug: dplessinger@axcelo.com
"The continued expansion of the ADAPT ...
www.argostherapeutics.com, 24 Sept 2013 [cached]
"The continued expansion of the ADAPT study to key centers in Europe and Israel demonstrates the increasing excitement and support throughout the international community in advancing cancer immunotherapy research," said Doug Plessinger, VP of Clinical and Medical Affairs of Argos Therapeutics.
"Activating the ADAPT study across ...
www.argostherapeutics.com, 6 June 2013 [cached]
"Activating the ADAPT study across several top cancer centers in the U.S. and expanding to key centers in Europe, Canada and Israel in the coming months, provides us with great confidence we are now on track to fully enroll the trial by mid-2014," said Doug Plessinger, VP of Clinical and Medical Affairs of Argos Therapeutics.
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304